A patient with combined polycystic ovary syndrome and autoimmune polyglandular syndrome type 2

Gynecological Endocrinology

Volumn 23, Issue 5, 2007, Pages 252-256

  Lee, Seung Hwan ^a   Kim, Mee Ran ^a   Kim, Ji Hyun ^a   Kwon, Hyuk Sang ^a   Yoon, Kun Ho ^a   Son, Ho Young ^a   Cha, Bong Yun ^a,b  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Amenorrhea; Autoimmune polyglandular syndrome; Diabetes; Polycystic ovary syndrome; Thyroiditis

Indexed keywords

GLUTAMATE DECARBOXYLASE 65 ANTIBODY; IA ANTIBODY; INSULIN; MEDROXYPROGESTERONE; MINOXIDIL; THYROXINE;

ADULT; ALOPECIA; ANTIBODY DETECTION; ARTICLE; AUTOIMMUNE THYROIDITIS; CASE REPORT; CLINICAL FEATURE; FEMALE; HUMAN; HYPERGLYCEMIA; HYPOTHYROIDISM; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; MULTIPLE ENDOCRINE ADENOMATOSIS; OVARY POLYCYSTIC DISEASE; POLYDIPSIA; POLYURIA; PRIORITY JOURNAL; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT REDUCTION;

ADULT; DIABETES MELLITUS, TYPE 1; FEMALE; HASHIMOTO DISEASE; HUMANS; POLYCYSTIC OVARY SYNDROME; POLYENDOCRINOPATHIES, AUTOIMMUNE;

EID: 34250206953     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590701297658     Document Type: Article

References (25)

1. Neufeld M, Blizzard RM. Polyglandular autoimmune diseases. In: Pinchera A, Doniach D, Fenzi GF, Basschieri L, editors. Symposium on autoimmune aspects of endocrine disorders. New York: Academic Press; 1980. pp 357-365.
2. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
3. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, et al. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006;91:4237-4245.
4. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, editors. Polycystic ovary syndrome. Boston (MA): Blackwell Scientific Publications; 1992. pp 377-384.
5. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141-146.
6. Escobar-Morreale HF, Roldán B, Barrio R, Alonso M, Sancho J, de la Calle H, García-Robles R. High prevalence of the polycystic ovary syndrome and hirsutism in women with type 1 diabetes mellitus. J Clin Endocrinol Metab 2000;85:4182-4187.
7. Codner E, Soto N, Lopez P, Trejo L, Ávila A, Eyzaguirre FC, Íniguez G, Cassorla F. Diagnostic criteria for polycystic ovary syndrome and ovarian morphology in women with type 1 diabetes mellitus. J Clin Endocrinol Metab 2006;91:2250-2256.
8. Pedersen O, Beck-Nielsen H. Insulin resistance and insulin-dependent diabetes mellitus. Diabetes Care 1987;10:516-523.
9. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005;352:1223-1236.
10. Ykijarvinen H, Makimattila S, Utriainen T, Rutanen EM. Portal insulin concentrations rather than insulin sensitivity regulate serum sex hormone-binding globulin and insulin-like growth factor binding protein 1 in vivo. J Clin Endocrinol Metab 1995;80:3227-3232.
11. Janssen OE, Mehlmauer N, Hahn S, Offner AH, Gärtner R. High prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome. Eur J Endocrinol 2004;150:363-369.
12. Olsen NJ, Kovacs WJ. Effects of androgens on T and B lymphocyte development. Immunol Res 2001;23:281-288.
13. Paavonen T. Hormonal regulation of immune responses. Ann Med 1994;26:255-258.
14. Ghosh S, Kabir SN, Pakrashi A, Chatterjee S, Chakravarty B. Subclinical hypothyroidism: a determinant of polycystic ovary syndrome. Horm Res 1994;41:43-44.
15. Hoek A, Schoemaker J, Drexhage HA. Premature ovarian failure and ovarian autoimmunity. Endocr Rev 1997;18:107-134.
16. Fénichel P, Gobert B, Carré Y, Barbarino-Monnier P, Hiéronimus S. Polycystic ovary syndrome in autoimmune disease. Lancet 1999;353:2210.
17. van Gelderen CJ, Gomes dos Santos ML. Polycystic ovarian syndrome. Evidence for an autoimmune mechanism in some cases. J Reprod Med 1993;38:381-386.
18. Rojansky N, Roll D, Meirow D. Polycystic ovary syndrome. An autoimmune disease? J Reprod Med 1997;42:325-328.
19. Reimand K, Talja I, Metsküla K, Kadastik Ü, Matt K, Uibo R. Autoantibody studies of female patients with reproductive failure. J Reprod Immunol 2001;51:167-176.
20. Cela E, Robertson C, Rush K, Kousta E, White DM, Wilson H, Lyons G, Kingsley P, McCarthy MI, Franks S. Prevalence of polycystic ovaries in women with androgenic alopecia. Eur J Endocrinol 2003;149:439-442.
21. Yildiz BO. Diagnosis of hyperandrogenism: clinical criteria. Best Pract Res Clin Endocrinol Metab 2006;20:167-176.
22. Hedstrand H, Ekwall O, Haavik J, Landgren E, Betterle C, Perheentupa J, Gustafsson J, Husebye E, Rorsman F, Kampe O. Identification of tyrosine hydroxylase as an autoantigen in autoimmune polyendocrine syndrome type 1. Biochem Biophys Res Commun 2000;267:456-461.
23. Gordon GG, Southren AI, Calanog A, Olivo J, Rafii F. The effect of medroxyprogesterone acetate on androgen metabolism in the polycystic ovary syndrome. J Clin Endocrinol Metab 1972;35:444-447.
24. Roldán B, Escobar-Morreale HF, Barrio R, de la Calle H, Alonso M, García-Robles R, Sancho J. Identification of the source of androgen excess in hyperandrogenic type 1 diabetic patients. Diabetes Care 2001;24:1297-1299.
25. Virdis R, Zampolli M, Street ME, Vanelli M, Potau N, Terzi C, Ghizzoni L, Ibanez L. Ovarian 17α-hydroxyprogesterone responses to GnRH analog testing in oligomenorrheic insulin-dependent diabetic adolescents. Eur J Endocrinol 1997;136:624-629.